Harvard's Wyss Institute partners with Cellectis to recode the human genome

(Wyss Institute for Biologically Inspired Engineering at Harvard) Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that they will collaborate to further advance the Wyss Institute's efforts to recode the entire genome of cell lines derived from humans and other species, and to develop new tools and methods facilitating this goal.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news